European Commission

#European Commission #European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders #Neuroscience

EC approves first treatment for rare neurodegenerative disease

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients.  It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is… Read More

#Editor's Choice #News #Regulatory

Lungs
#Asthma #AstraZeneca #European Commission #European Medicines Agency

EC approves first triple-combination therapy for asthma maintenance

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF) has been approved in the European Union (EU) as a maintenance treatment for asthma.  It is approved in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose… Read More

#News #Regulatory

Bispecific antibodies
#Bispecific Antibodies #European Commission #Johnson & Johnson #Myeloma #Oncology

EC okays immunotherapy double regimen for multiple myeloma

The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care.  The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have… Read More

#News #Regulatory

European Commission
#AbbVie #European Commission #Follicular lymphoma #Genmab

EC grants marketing authorisation to lymphoma therapy 

The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma.  The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in… Read More

#News #Regulatory

#European Commission #European Union #Muscular dystrophy

Approval makes spinal muscular atrophy cream available in EU 

The European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA).  Itvisma can now be used in the European Union by children two years and older, teens and adults living with 5q SMA with a bi-allelic mutation in the survival motor neuron 1… Read More

#News #Regulatory

Colon cancer
#Colorectal cancer #European Commission #Pierre Fabre Laboratories

EC approves metastatic colorectal cancer combination regimen 

The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer.  Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).  The approval is based on the results from the… Read More

#News #Regulatory

European Commission
#European Commission #Measles

Marketing authorisation granted to measles therapy 

The European Commission has granted marketing authorisation to a treatment reducing the risk of measles in non-vaccinated patients.  Privigen, developed by CSL, is a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. Read More

#News

#Animal models #Animal testing #European Commission

European Commission pledges to phase out animal testing 

The European Commission has said it is “firmly committed to phasing out animal testing” as it launches a roadmap for chemical safety assessments.  The latest statistics on animal use for the EU and Norway show over 9.1 million animals were used in scientific tests and experiments in the EU and Norway in 2023. This includes… Read More

#News

European Commission
#Clinical trial #European Commission #TK2d

EC grants marketing authorisation to rare disease drug 

The European Commission (EC) has granted marketing authorisation for Kygevvi (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d).  The approval, making Kygevvi the first and only treatment for TK2d, can now be used to treat paediatric and adult patients with the condition with… Read More

#News #Regulatory

European Commission
#European Commission #Incyte #Monoclonal antibodies #Oncology

European Commission approves retifanlimab for anal cancer

The European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).  Rretifanlimab is the first systemic treatment for adult patients with advanced… Read More

#News #Regulatory

Doctor showing a model of the prostate
#European Commission #Johnson & Johnson #Oncology #Prostate cancer

Dual action prostate cancer drug gets expanded indication in EU

The European Commission has approved an indication extension for Akeega (niraparib and abiraterone acetate dual action tablet) with prednisone or prednisolone (AAP) in combination with androgen deprivation therapy (ADT).  The regimen is now also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and… Read More

#News #Regulatory

Weight loss concept
#European Commission #Novo Nordisk #Obesity

Higher dosage of Wegovy more effective for weight loss 

The European Commission (EC) has approved a higher dosage of obesity drug Wegovy which has proved it can help adults lose weight more effectively.  Final approval has been granted to a new 7.2mg once-weekly maintenance dose of Wegovy (semaglutide injection), giving doctors another treatment option alongside the previous 2.4mg… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#CHMP #European Commission #European Medicines Agency #Genetic diseases #Rare diseases #UCB

Kygevvi recommended in the EU for thymidine kinase 2 deficiency

UCB’s Kygevvi (doxecitine and doxribtimine) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation under exceptional circumstances.  The recommendation is for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase… Read More

#News #Regulatory

T cells attack a cancer cell
#CHMP #European Commission #Immunotherapy #Incyte #Oncology

CHMP recommends first PD-1 immunotherapy for rare cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy).  If it is approved by the European Commission it will be the first… Read More

#News #Regulatory

Male patient with doctor
#CHMP #European Commission #Johnson & Johnson #Oncology #Prostate cancer

J&J drug gets EU green light for prostate cancer

Johnson & Johnson’s Akeega (niraparib and abiraterone acetate dual action tablet) could soon be available to EU patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The recommendation is for niraparib and abiraterone… Read More

#News #Regulatory

European Commission
#European Commission #GSK #Respiratory syncytial virus #Vaccines

European Commission approves RSV vaccine 

The European Commission (EC) has approved a respiratory syncytial virus (RSV) vaccine for the treatment of adult patients with lower respiratory tract disease (LRTD) caused by RSV.  Arexy, an adjuvanted recombinant RSV vaccine developed by GSK, will now be available to adult patients in European countries. The… Read More

#News #Regulatory